相似文献
1
Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease.
JAMA Netw Open. 2022 Nov 1;5(11):e2242140. doi: 10.1001/jamanetworkopen.2022.42140.
2
Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
J Med Virol. 2023 Dec;95(12):e29318. doi: 10.1002/jmv.29318.
3
Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
J Med Virol. 2023 Apr;95(4):e28756. doi: 10.1002/jmv.28756.
4
Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.
Open Forum Infect Dis. 2022 Aug 3;9(8):ofac389. doi: 10.1093/ofid/ofac389. eCollection 2022 Aug.
5
Nirmatrelvir Plus Ritonavir: First Approval.
Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.
6
Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19.
J Infect. 2023 Jun;86(6):e158-e160. doi: 10.1016/j.jinf.2023.03.023. Epub 2023 Mar 30.
7
Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multi-centre retrospective study in China.
Int J Antimicrob Agents. 2023 Aug;62(2):106857. doi: 10.1016/j.ijantimicag.2023.106857. Epub 2023 May 19.
8
Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19.
J Med Virol. 2023 Jun;95(6):e28836. doi: 10.1002/jmv.28836.
9
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.
Ann Intern Med. 2023 Oct;176(10):eL230264. doi: 10.7326/L23-0264.
10
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.
Ann Intern Med. 2023 Oct;176(10):eL230265. doi: 10.7326/L23-0265.
引用本文的文献
1
Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data.
Curr Drug Metab. 2024;25(9):639-652. doi: 10.2174/0113892002320326250123082112.
2
Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study.
J Pharm Health Care Sci. 2024 Sep 3;10(1):54. doi: 10.1186/s40780-024-00376-4.
3
COVID-19 therapeutics.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0011923. doi: 10.1128/cmr.00119-23. Epub 2024 May 21.
4
Physician characteristics associated with antiviral prescriptions for older adults with COVID-19 in Japan: an observational study.
BMJ Open. 2024 Mar 15;14(3):e083342. doi: 10.1136/bmjopen-2023-083342.
5
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review.
Life (Basel). 2024 Feb 1;14(2):214. doi: 10.3390/life14020214.
6
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
J Korean Med Sci. 2024 Feb 19;39(6):e52. doi: 10.3346/jkms.2024.39.e52.
7
The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review.
Life (Basel). 2023 Dec 11;13(12):2322. doi: 10.3390/life13122322.
8
Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study.
Infect Chemother. 2023 Dec;55(4):490-499. doi: 10.3947/ic.2023.0087. Epub 2023 Nov 22.
9
Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study.
Pharmaceuticals (Basel). 2023 Aug 4;16(8):1107. doi: 10.3390/ph16081107.
10
Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials.
Transfusion. 2023 Sep;63(9):1639-1648. doi: 10.1111/trf.17485. Epub 2023 Aug 3.
本文引用的文献
1
Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.
Open Forum Infect Dis. 2022 Aug 3;9(8):ofac389. doi: 10.1093/ofid/ofac389. eCollection 2022 Aug.
2
Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study.
Transl Psychiatry. 2022 Mar 3;12(1):90. doi: 10.1038/s41398-022-01804-5.
3
Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study.
Clin Pharmacol Ther. 2021 Dec;110(6):1498-1511. doi: 10.1002/cpt.2317. Epub 2021 Jul 2.
4
Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study.
Mol Psychiatry. 2021 Sep;26(9):5199-5212. doi: 10.1038/s41380-021-01021-4. Epub 2021 Feb 4.
5
Factors associated with COVID-19-related death using OpenSAFELY.
Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.
Zotero 插件